Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
- 31 March 2004
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 43 (3) , 317-322
- https://doi.org/10.1016/j.lungcan.2003.10.010
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Targeting epidermal growth factor receptor in lung cancerCurrent Oncology Reports, 2002
- Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594Cancer, 2001
- The EGF receptor family as targets for cancer therapyOncogene, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1999
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958